Physician profile
Gary Lee Johnson
NPI 1750300430
$178,150.37
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $17K · 2021: $14K · 2022: $10K · 2023: $49K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Travel and Lodging: $8,432 · Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,629.50 |
| Travel and Lodging | $8,431.81 |
| Food and Beverage | $1,720.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $30,915.37 | 2019-2023 | Evobrutinib |
| Genentech USA, INC. | $27,235.24 | 2019-2025 | Xolair, Ocrevus, Vabysmo |
| Sunovion Pharmaceuticals INC. | $13,100.64 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12,588.12 | 2023-2025 | Caplyta |
| Genentech, INC. | $12,299.57 | 2019-2023 | Xolair |
| Lilly USA, LLC | $8,790.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $8,580.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $8,560.34 | 2020-2023 | |
| Leo Pharma INC. | $6,339.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $5,149.97 | 2022-2023 | |
| Lundbeck LLC | $4,962.09 | 2020-2021 | |
| Viiv Healthcare Company | $4,500.00 | 2023 | |
| Blue Earth Diagnostics | $3,964.11 | 2019 | |
| Bioventus LLC | $3,873.85 | 2019 | |
| Seagen INC. | $3,800.00 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,623.32 | 2019 | |
| Kyowa Kirin, INC. | $3,601.36 | 2019 | |
| Incyte Corporation | $2,997.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,226.00 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $1,841.87 | 2021-2023 | Imbruvica |
| Apellis Pharmaceuticals, INC. | $1,800.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $1,680.00 | 2021 | |
| Optinose US, INC. | $1,256.55 | 2019 | |
| Abbvie INC. | $1,225.00 | 2020 | |
| Gilead Sciences, INC. | $1,133.36 | 2019 | |
| Amgen INC. | $1,065.00 | 2022 | |
| Genzyme Corporation | $1,041.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.